Effect of neuraminidase inhibitor-resistant mutations on pathogenicity of clade 2.2 A/Turkey/15/06 (H5N1) influenza virus in ferrets
- PMID: 20523902
- PMCID: PMC2877746
- DOI: 10.1371/journal.ppat.1000933
Effect of neuraminidase inhibitor-resistant mutations on pathogenicity of clade 2.2 A/Turkey/15/06 (H5N1) influenza virus in ferrets
Abstract
The acquisition of neuraminidase (NA) inhibitor resistance by H5N1 influenza viruses has serious clinical implications, as this class of drugs can be an essential component of pandemic control measures. The continuous evolution of the highly pathogenic H5N1 influenza viruses results in the emergence of natural NA gene variations whose impact on viral fitness and NA inhibitor susceptibility are poorly defined. We generated seven genetically stable recombinant clade 2.2 A/Turkey/15/06-like (H5N1) influenza viruses carrying NA mutations located either in the framework residues (E119A, H274Y, N294S) or in close proximity to the NA enzyme active site (V116A, I117V, K150N, Y252H). NA enzyme inhibition assays showed that NA mutations at positions 116, 117, 274, and 294 reduced susceptibility to oseltamivir carboxylate (IC(50)s increased 5- to 940-fold). Importantly, the E119A NA mutation (previously reported to confer resistance in the N2 NA subtype) was stable in the clade 2.2 H5N1 virus background and induced cross-resistance to oseltamivir carboxylate and zanamivir. We demonstrated that Y252H NA mutation contributed for decreased susceptibility of clade 2.2 H5N1 viruses to oseltamivir carboxylate as compared to clade 1 viruses. The enzyme kinetic parameters (V(max), K(m) and K(i)) of the avian-like N1 NA glycoproteins were highly consistent with their IC(50) values. None of the recombinant H5N1 viruses had attenuated virulence in ferrets inoculated with 10(6) EID(50) dose. Most infected ferrets showed mild clinical disease signs that differed in duration. However, H5N1 viruses carrying the E119A or the N294S NA mutation were lethal to 1 of 3 inoculated animals and were associated with significantly higher virus titers (P<0.01) and inflammation in the lungs compared to the wild-type virus. Our results suggest that highly pathogenic H5N1 variants carrying mutations within the NA active site that decrease susceptibility to NA inhibitors may possess increased virulence in mammalian hosts compared to drug-sensitive viruses. There is a need for novel anti-influenza drugs that target different virus/host factors and can limit the emergence of resistance.
Conflict of interest statement
The authors declare no competing financial interests. While the study reported here did not utilize corporate funding, Drs. Natalia A. Ilyushina, Elena A. Govorkova, and Robert G. Webster are currently performing a different research study funded by F. Hoffmann-LaRoche, Ltd., Basel, Switzerland. In addition, the NA inhibitors oseltamivir carboxylate and zanamivir were provided by Hoffmann-La Roche, Ltd. (Basel, Switzerland).
Figures




Similar articles
-
Competitive fitness of oseltamivir-sensitive and -resistant highly pathogenic H5N1 influenza viruses in a ferret model.J Virol. 2010 Aug;84(16):8042-50. doi: 10.1128/JVI.00689-10. Epub 2010 Jun 2. J Virol. 2010. PMID: 20519385 Free PMC article.
-
Neuraminidase inhibitor-resistant recombinant A/Vietnam/1203/04 (H5N1) influenza viruses retain their replication efficiency and pathogenicity in vitro and in vivo.J Virol. 2007 Nov;81(22):12418-26. doi: 10.1128/JVI.01067-07. Epub 2007 Sep 12. J Virol. 2007. PMID: 17855542 Free PMC article.
-
Effect of an asparagine-to-serine mutation at position 294 in neuraminidase on the pathogenicity of highly pathogenic H5N1 influenza A virus.J Virol. 2011 May;85(10):4667-72. doi: 10.1128/JVI.00047-11. Epub 2011 Mar 2. J Virol. 2011. PMID: 21367898 Free PMC article.
-
Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance.Influenza Other Respir Viruses. 2013 Jan;7 Suppl 1(Suppl 1):25-36. doi: 10.1111/irv.12047. Influenza Other Respir Viruses. 2013. PMID: 23279894 Free PMC article. Review.
-
Neuraminidase inhibitor resistance in influenza viruses.J Med Virol. 2007 Oct;79(10):1577-86. doi: 10.1002/jmv.20951. J Med Virol. 2007. PMID: 17705169 Review.
Cited by
-
Multiple introductions of highly pathogenic avian influenza H5N1 viruses into Bangladesh.Emerg Microbes Infect. 2014 Feb;3(2):e11. doi: 10.1038/emi.2014.11. Epub 2014 Feb 12. Emerg Microbes Infect. 2014. PMID: 26038508 Free PMC article.
-
N-Glycan Profiles of Neuraminidase from Avian Influenza Viruses.Viruses. 2024 Jan 26;16(2):190. doi: 10.3390/v16020190. Viruses. 2024. PMID: 38399967 Free PMC article.
-
Pseudovirus-based neuraminidase inhibition assays reveal potential H5N1 drug-resistant mutations.Protein Cell. 2013 May;4(5):356-63. doi: 10.1007/s13238-013-2125-y. Epub 2013 Apr 15. Protein Cell. 2013. PMID: 23589018 Free PMC article.
-
Fitness of neuraminidase inhibitor-resistant influenza A viruses.Curr Opin Virol. 2011 Dec;1(6):574-81. doi: 10.1016/j.coviro.2011.08.006. Epub 2011 Oct 1. Curr Opin Virol. 2011. PMID: 22440915 Free PMC article. Review.
-
Viral Factors Associated With the High Mortality Related to Human Infections With Clade 2.1 Influenza A/H5N1 Virus in Indonesia.Clin Infect Dis. 2020 Mar 3;70(6):1139-1146. doi: 10.1093/cid/ciz328. Clin Infect Dis. 2020. PMID: 31321436 Free PMC article.
References
-
- World Health Organization. 2010. Cumulative number of confirmed human cases of avian influenza A/(H5N1) reported to WHO. World Health Organization. Available: http://www.who.int/csr/disease/avian_influenza/country/cases_table_2010_.... Accessed March 8 2010.
-
- Webster RG, Govorkova EA. H5N1 influenza – continuing evolution and spread. N Engl J Med. 2006;355:2174–2177. - PubMed
-
- Abdel-Ghafar AN, Chotpitayasunondh T, Gao Z, Hayden FG, Nguyen DH, et al. Update on avian influenza A (H5N1) virus infection in humans. N Engl J Med. 2008;358:261–273. - PubMed
-
- Moscona A. Medical management of influenza infection. Annul Rev Med. 2008;59:397–413. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical